Advertisement

RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF

Published on: 

Preliminary blinded data from the phase 2 RENEW trial showed 33% of evaluable patients with idiopathic pulmonary fibrosis (IPF) had improved forced vital capacity (FVC) from baseline at week 12, with no treatment-related serious adverse events, Rein Therapeutics announced November 16, 2026.1

The data are pooled across LTI-03 and placebo arms, and the company stated the results do not establish a treatment effect or permit comparison of LTI-03 with placebo.1 LTI-03 is a first-in-class inhaled peptide derived from caveolin-1 biology, designed to inhibit profibrotic signaling and protect alveolar epithelial cells.1 It holds FDA Orphan Drug and Fast Track designations for IPF.1,2

"The improvements in FVC from baseline observed in 33% of evaluable patients is particularly encouraging, as improvements in lung function are not expected in this patient population," said Cory Hogaboam, PhD, chief scientific officer, Rein Therapeutics.

RENEW trial design and enrollment

RENEW (NCT06968845) is a randomized, double-blind, placebo-controlled phase 2 trial evaluating 2 dose levels of LTI-03 vs placebo over 24 weeks.1 The primary endpoint is safety and tolerability, and secondary endpoints include change from baseline in FVC, quantitative high-resolution CT, and exploratory biomarkers of epithelial injury and fibrosis.1

As of the announcement, 90 of approximately 120 planned patients had been randomized at sites in the US, UK, Australia, Germany, Poland, Bulgaria, and Romania.1 The company described enrollment as ahead of schedule.1

Blinded week 12 FVC and safety observations

Among 24 patients with evaluable baseline and week 12 FVC data, 8 (33%) improved from baseline, 11 (46%) declined by 5.7% or less, and 5 (21%) declined by more than 5.7%.1 Using a 5% threshold, 18 patients (75%) improved or declined by less than 5%.1 Individual changes ranged from a gain of 338 mL to a decline of 349 mL.1

The 5.7% threshold was drawn from an external meta-analysis of placebo arms in IPF trials, and the company characterized it as descriptive rather than a validated measure of treatment response.1

As of the interim cutoff, no serious adverse events (AEs) were assessed as related to study treatment.1 AEs were mostly mild or moderate, cough was the most frequently reported, and 92% of enrolled participants remained on or had completed the study.1

"We remain committed to advancing the study toward completion and look forward to reporting unblinded topline data in 2027," said Brian Windsor, PhD, president and chief executive officer, Rein Therapeutics.

Rein expects its current cash to fund operations into the first quarter of 2028, through completion of RENEW.1 The FDA lifted a clinical hold on LTI-03 in October 2025.1

References
  1. Rein Therapeutics. Rein Therapeutics announces preliminary blinded phase 2 RENEW data showing encouraging lung function trends in patients with idiopathic pulmonary fibrosis and reports third quarter 2026 financial results. Published November 16, 2026. Accessed November 16, 2026. https://investors.aileronrx.com/news-releases/news-release-details/rein-therapeutics-announces-preliminary-blinded-phase-2-renew
  2. HCPLive. FDA fast tracks LTI-03 for idiopathic pulmonary fibrosis. Published August 20, 2026. Accessed November 16, 2026. https://www.hcplive.com/view/fda-fast-tracks-lti-03-for-idiopathic-pulmonary-fibrosis

Advertisement
Advertisement